Day One Biopharmaceuticals (DAWN) Invested Capital: 2022-2025
Historic Invested Capital for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $450.9 million.
- Day One Biopharmaceuticals' Invested Capital fell 18.83% to $450.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $450.9 million, marking a year-over-year decrease of 18.83%. This contributed to the annual value of $502.8 million for FY2024, which is 45.08% up from last year.
- Per Day One Biopharmaceuticals' latest filing, its Invested Capital stood at $450.9 million for Q3 2025, which was down 2.16% from $460.8 million recorded in Q2 2025.
- Over the past 5 years, Day One Biopharmaceuticals' Invested Capital peaked at $555.5 million during Q3 2024, and registered a low of $259.6 million during Q1 2022.
- Its 3-year average for Invested Capital is $410.5 million, with a median of $426.1 million in 2023.
- In the last 5 years, Day One Biopharmaceuticals' Invested Capital decreased by 28.01% in 2024 and then skyrocketed by 61.56% in 2025.
- Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Invested Capital stood at $332.0 million in 2022, then climbed by 4.37% to $346.5 million in 2023, then spiked by 45.08% to $502.8 million in 2024, then decreased by 18.83% to $450.9 million in 2025.
- Its Invested Capital was $450.9 million in Q3 2025, compared to $460.8 million in Q2 2025 and $479.5 million in Q1 2025.